Announcements Trials
Browse Landscape

Phase

Phase 2 18Phase 3 12Phase 1 9Phase 1/2 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 24Terminated 4Completed 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Rectal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 69Nivolumab 39Cyclophosphamide 35Carboplatin 27Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 20Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16Ipilimumab 16fludarabine 15Bevacizumab 15Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Cisplatin 12Azacitidine 12belantamab mafodotin 11Pemetrexed 11Docetaxel 11Calcium Dobesilate 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × abemaciclib × Clear all
NCT05548127 2026-02-10

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Pfizer

Phase 1/2 Active not recruiting
37 enrolled
Breast

Breast Neoplasms

NCT04616183 2025-12-23

LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
46 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡